Ισραήλ - Αγγλικά - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 10000 iu/ml - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium -

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 10000 iu/ml - solution for injection - 10000 iu/ml - active: dalteparin sodium 10000 iu/ml excipient: sodium chloride water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 12500 iu/ml - solution for injection - 12500 iu/ml - active: dalteparin sodium 12500 iu/ml excipient: water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 25000 iu/ml - solution for injection - 25000 iu/ml - active: dalteparin sodium 25000 iu/ml excipient: water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - dalteparin sodium (unii: 12m44vtj7b) (dalteparin - unii:s79o08v79f) - dalteparin sodium 2500 [iu] in 0.2 ml - fragmin injection is indicated for the prophylaxis of ischemic complications in unstable angina and non-q-wave myocardial infarction, when concurrently administered with aspirin therapy [see clinical studies (14.1)] . fragmin is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): fragmin is indicated for the extended treatment of symptomatic venous thromboembolism (vte) (proximal dvt and/or pe), to reduce the recurrence of vte in adult patients with cancer. in these patients, the fragmin therapy begins with the initial vte treatment and continues for six months [see clinical studies (14.5)] . fragmin is indicated for the treatment of symptomatic venous thromboembolism (vte) to reduce the recurrence of vte in pediatric patients 1 month of age and older. fragmin is not indicated for the acute treatment of vte. fragmin is contraindicated in: risk summary available data from published literature and postmarketing reports have not reported a clear association wit

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - dalteparin sodium - solution for injection - 25000unit/1ml

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - dalteparin sodium - solution for injection - 25000unit/1ml

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - dalteparin sodium - solution for injection - 25000unit/1ml

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - dalteparin sodium - solution for injection - 25000unit/1ml